Stroke test company seeks to raise $9 million:
This article was originally published in Clinica
Proteome Sciences is to raise £6 million ($$9.4 million) from an open one for eight offer, priced at 45p. The UK listed company, which was founded in 1984, is developing a blood test for stroke and other disorders, based on changes in protein expression. The Cobham, Surrey-based proteomics company also has in development a high specificity and sensitivity test for Creutzfeldt-Jakob disease (CJD) and other transmissable spongiform encephalopathies.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.